

(12) International Application Status Report

Received at International Bureau: 29 January 2015 (29.01.2015)

Information valid as of: 07 July 2015 (07.07.2015)

Report generated on: 01 July 2016 (01.07.2016)

(10) Publication number:

WO2015/110707

(43) Publication date:

30 July 2015 (30.07.2015)

(26) Publication language:

English (EN)

(21) Application Number:

PCT/FI2015/050041

(22) Filing Date:

23 January 2015 (23.01.2015)

(25) Filing language:

English (EN)

(31) Priority number(s):

20145073 (FI)

(31) Priority date(s):

24 January 2014 (24.01.2014)

(31) Priority status:

Priority document received (in compliance with PCT Rule 17.1)

(51) International Patent Classification:

A61K 38/48 (2006.01); C12N 9/64 (2006.01)

(71) Applicant(s):

UNIVERSITY OF HELSINKI [FI/FI]; Yliopistonkatu 4 FI-00014 University of Helsinki (FI) *(for all designated states)*

(72) Inventor(s):

ALITALO, Kari; c/o University of Helsinki Yliopistonkatu 4 FI-00014 University of Helsinki (FI)
JELTSCH, Michael; c/o University of Helsinki Yliopistonkatu 4 FI-00014 University of Helsinki (FI)
JHA, Sawan Kumar; c/o University of Helsinki Yliopistonkatu 4 FI-00014 University of Helsinki (FI)
TVOROGOV, Denis; c/o University of Helsinki Yliopistonkatu 4 FI-00014 University of Helsinki (FI)

(74) Agent(s):

KOLSTER OY AB; (Iso Roobertinkatu 23) P.O.Box 148 FI-00121 Helsinki (FI)

(54) Title (EN): METHODS AND USES RELATED TO ADAMTS3

(54) Title (FR): PROCÉDÉS ET UTILISATIONS LIÉS À ADAMTS3

(57) Abstract:

(EN): The present invention relates to the utilization of ADAMTS3 metalloprotease. More specifically, the present invention relates to a method of producing fully processed mature VEGF-C polypeptide by a cell and a method of cleaving VEGF-C polypeptides. Furthermore, the present invention relates to different uses of ADAMTS3, ADAMTS3 inhibitors or compositions comprising ADAMTS3 or ADAMTS3 inhibitors, and a method of treating a lymphatic disorder. In addition, the invention relates to a method of producing VEGF-C binding molecules.

(FR): La présente invention concerne l'utilisation de la métalloprotéase ADAMTS3. La présente invention concerne plus spécifiquement un procédé de production d'un polypeptide VEGF-C mature totalement traité par une cellule et un procédé de clivage des polypeptides VEGF-C. La présente invention concerne également différentes utilisations d'ADAMTS3, des inhibiteurs d'ADAMTS3 ou des compositions comprenant ADAMTS3 ou des inhibiteurs d'ADAMTS3, et un procédé de traitement d'un trouble lymphatique. La présente invention concerne en outre un procédé de production de molécules liant le VEGF-C.

International search report:

Received at International Bureau: 27 April 2015 (27.04.2015) [EP]

International Report on Patentability (IPRP) Chapter II of the PCT:

Not available

(81) Designated States:

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ,

LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG
African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW

Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM

Declarations:

Declaration made as applicant's entitlement, as at the international filing date, to apply for and be granted a patent (Rules 4.17(ii) and 51bis.1(a)(ii)), in a case where the declaration under Rule 4.17(iv) is not appropriate

Declaration of inventorship (Rules 4.17(iv) and 51bis.1(a)(iv)) for the purposes of the designation of the United States of America